Here are 1-3 brief analogies to describe Vor Biopharma:

• Like a specialized CRISPR Therapeutics, but instead of correcting disease-causing genes, Vor uses gene editing to make a patient's healthy stem cells resistant to powerful cancer treatments.

• Vor Biopharma is like the 'Intel Inside' for certain targeted cancer therapies, developing a critical biological component (engineered stem cells) that allows other companies' powerful drugs to safely destroy cancer cells without harming healthy tissue.

• VOR33: An engineered hematopoietic stem cell (eHSC) product candidate in clinical trials for treating acute myeloid leukemia (AML) and other hematological malignancies.
• eHSC Targeted Therapies: A platform for developing therapies, including CAR-Ts, bispecific antibodies, and antibody-drug conjugates, designed to treat blood cancers.

As a clinical-stage biopharmaceutical company, Vor Biopharma (VOR) is currently focused on the research and development of its engineered hematopoietic stem cell (eHSC) therapies, such as VOR33, which is in Phase 1/2 clinical trials. At this stage, the company does not have commercial products available for sale and therefore does not have major customers in the traditional sense. Its activities are centered on clinical development, regulatory processes, and potentially partnerships or licensing agreements in the future once its therapies are approved.

Major Suppliers:

• Akron BioProducts (private company)

Jean-Paul Kress, MD Chief Executive Officer and Chairman

Dr. Kress brings decades of executive leadership experience in the pharmaceutical and biotech industries. He most recently served as Chief Executive Officer of MorphoSys, where he led the development, approval, and commercialization of Monjuvi® (tafasitamab). He also advanced MorphoSys' pipeline through the landmark acquisition of Constellation Pharmaceuticals in 2021, which strengthened MorphoSys' position in oncology innovation and ultimately led to its subsequent acquisition by Novartis in 2024.

Sandy Mahatme Chief Financial Officer, Chief Business Officer

Mr. Mahatme has over 30 years of executive leadership experience in the biopharmaceutical industry, with a strong background in capital markets, business development, global operations, and shareholder value creation. He co-founded National Resilience, Inc., a biomanufacturing company, where he most recently served as President, Chief Operating Officer, and Chief Financial Officer. Before that, he was Executive Vice President, Chief Financial Officer, and Chief Business Officer at Sarepta Therapeutics, where he led capital formation efforts exceeding $3.5 billion. Mr. Mahatme also held senior positions at Celgene Corporation, Pfizer, Inc., and Ernst & Young, LLP. He currently serves on the boards of CRISPR Therapeutics and Idorsia Pharmaceuticals.

Jeremy Sokolove, MD Chief Medical Officer

Dr. Sokolove is the Chief Medical Officer at Vor Biopharma.

Dallan Murray Chief Commercial Officer

Mr. Murray brings more than 25 years of experience leading commercial strategy, global product launches, and customer-facing organizations in biotechnology and pharmaceutical companies. He previously served as Executive Vice President, Chief Customer Officer at Sarepta Therapeutics, where he led the commercial and medical affairs organizations and the international business unit, contributing to approximately $1.8 billion in net product revenue in 2024.

Adi Osovsky, SJD General Counsel

Dr. Osovsky serves as the General Counsel for Vor Biopharma.

1. High Uncertainty Regarding Strategic Transformation and Financial Viability: Vor Biopharma undertook a substantial strategic shift in May 2025, halting its primary engineered hematopoietic stem cell (eHSC) development programs for cancer, including its lead candidates trem-cel (formerly VOR33) and VCAR33. This decision was attributed to disappointing clinical results and a challenging fundraising environment, leading to a significant workforce reduction of approximately 95% and the winding down of clinical and manufacturing operations. Subsequently, the company pivoted by acquiring global rights to telitacicept, an autoimmune therapy already approved in China. This drastic change in strategic direction introduces substantial uncertainty about Vor Biopharma's ability to successfully execute its new multifaceted strategy, secure adequate ongoing funding, and achieve long-term financial viability.
2. Clinical Development and Regulatory Approval Risk for Product Candidates: Despite some positive Phase 3 data for telitacicept in China, its path to approval in major markets like the U.S. and Europe is not guaranteed. It will require extensive and costly clinical trials and navigating complex regulatory hurdles. Although the company had cited "disappointing clinical results" for its original eHSC programs, some recent information suggests a continued or renewed effort around trem-cel (VOR33) and VCAR-017, potentially moving them into expanded AML cohorts. Any such ongoing or re-initiated eHSC development efforts will face the inherent high failure rates typical of early-stage clinical development, coupled with complex manufacturing and logistical challenges unique to cell and gene therapies.
3. Intense Competitive Landscape: Vor Biopharma operates in highly competitive therapeutic areas. For its acquired autoimmune therapy, telitacicept, the company will compete against established treatments and numerous other drugs in development targeting multi-billion dollar autoimmune markets. If Vor Biopharma continues to pursue its eHSC platform in oncology, it will face significant competition from other developers of engineered cell therapies, CAR-T treatments, and other therapies for acute myeloid leukemia (AML) and related hematological malignancies. This intense competition could significantly impact market penetration and commercial success, even if therapies achieve regulatory approval.

For Vor Biopharma (VOR), the expected drivers of future revenue growth over the next 2-3 years are primarily centered on the advancement and potential commercialization of telitacicept for autoimmune diseases, following a significant strategic pivot by the company in June 2025.

1. Successful Global Commercialization of Telitacicept for Generalized Myasthenia Gravis (gMG): Vor Biopharma is focused on advancing telitacicept, a novel dual-target fusion protein, through a global Phase 3 clinical trial for generalized myasthenia gravis (gMG) to support potential regulatory approvals and commercialization in key markets such as the United States, Europe, and Japan. This represents the most advanced and direct pathway to generating product revenue for the company.
2. Expansion of Telitacicept into Additional Autoimmune Indications and Geographies (ex-Greater China): Telitacicept has demonstrated positive Phase 3 results in Sjögren's disease and is already approved in China for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Future revenue growth is anticipated from pursuing regulatory approvals and subsequent commercialization of telitacicept for these or other autoimmune conditions in territories outside of Greater China, significantly broadening its market reach and revenue potential.
3. Milestone Payments and Royalties from the RemeGen Licensing Agreement: Vor Biopharma's licensing agreement with RemeGen for ex-Greater China rights to telitacicept includes potential milestone payments that could reach up to $4 billion, in addition to royalties on future sales. These payments are expected to contribute to the company's revenue as telitacicept progresses through clinical development, achieves regulatory approvals, and is commercialized in the licensed territories.
4. Strategic Partnerships and Licensing Agreements for the Engineered Hematopoietic Stem Cell (eHSC) Platform: While the company's primary focus has shifted, Vor Biopharma's engineered hematopoietic stem cell (eHSC) platform, including its lead candidate VOR33, remains an asset for potential revenue generation through strategic collaborations. The company aims to pursue co-development, licensing deals, and non-dilutive funding by partnering its eHSC "shield-and-target" approach with oncology innovators developing CAR-Ts, bispecific antibodies, and antibody-drug conjugates.

Capital Allocation Decisions for Vor Biopharma (VOR)

Share Repurchases

• Vor Biopharma made minor share repurchases, with a dollar amount of $1.2 million in 2023 and $0.3 million in 2024.

Share Issuance

• In December 2025, Vor Biopharma raised approximately $150 million through a private placement by selling 13.9 million shares of common stock at $10.81 per share.
• The company completed an underwritten public offering in November 2025, raising $100 million by selling 10 million shares of common stock at $10.00 per share.
• In August 2024, Vor Biopharma successfully raised $110 million in a Series C funding round.

Inbound Investments

• A private placement in December 2025 saw participation from institutional investors including RA Capital Management, Forbion, Frazier Life Sciences, Caligan Partners, Logos Capital, and Venrock Healthcare Capital Partners.
• The August 2024 Series C funding round was led by 5AM Ventures, Fidelity, SR One, Novartis Venture Fund, and Cormorant Asset Management.
• As part of a licensing deal for telitacicept in June 2025, Vor Biopharma issued $80 million worth of warrants to a RemeGen subsidiary, granting them a 23% stake in Vor.

Outbound Investments

• In June 2025, Vor Biopharma made an upfront payment of $45 million to RemeGen to acquire exclusive ex-China rights to telitacicept, an autoimmune asset.

Capital Expenditures

• Vor Biopharma reported capital expenditures of approximately $0.2 million in 2024 and $1.1 million in 2023.
• In Q3 2025, the company invested $244,000 in capital expenditures, primarily for funding long-term assets and infrastructure.
• Capital expenditures for the last 12 months ending in early 2026 were approximately $699,000.